Showing 3451-3460 of 9296 results for "".
- ADAM Accepting Nominations for Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-accepting-nominations-for-practice-manager-of-the-year/2458363/The Association of Dermatology Administrators and Managers is accepting nominations for its annual Practice Manager of the Year Award. Now in its fourth year, the Practice Manager of the Year Award recognizes the office professional who best demonstrates innovative thinking, insight and leadership …
- Merz On The Move: Reflections On Fiscal Year 2015/16https://practicaldermatology.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2458365/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year (EUR 1,157.0 million) as a result of lower royalties for…
- NPF Offers Open Enrollment Insurance Advice Via New Patient Navigation Centerhttps://practicaldermatology.com/news/national-psoriasis-foundation-offers-open-enrollment-insurance-advice-via-new-patient-navigation-center/2458380/The National Psoriasis Foundation (NPF) Patient Navigation Center aims to help patients learn more about psoriatic disease, how to manage their condition and get answers to specific insurance and access-to-care questions thoughout the open enrollment period. The period to make changes to Medicare …
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device BF-RhodoLE…
- Meet the Newest Filler on the Block: Biologica Technologies' Allofill™https://practicaldermatology.com/news/meet-the-newest-filler-on-the-block-biologica-technologies-allofill/2458412/A newly launched off-the-shelf fat-derived filler may provide the long-lasting results associated with fat grafting plus the convenience of other ready-to-use injectables. Allofill is Biologica Technologies’ first foray into aesthetics. The company has products in the orthopedic space. Launched i…
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on psoriasis which highlighted how the current lack of psoria…
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global Market and is expected to begin …
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now three FDA-appro…
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market, and Kybella may be the gateway treatment for men just as Botox was…
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to the study, which…